




**MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in *BRAF* mutated colorectal cancer**

**Supplementary Figures**

# Supplementary Fig.S1



# Supplementary Fig.S2



# Supplementary Fig.S3

